Astellas Pharma China, Inc.

Clinical trials sponsored by Astellas Pharma China, Inc., explained in plain language.

Now part of Astellas Pharma Inc. 4503 TOKYO

The Chinese subsidiary of Astellas Pharma, a global pharmaceutical company.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Completed 1

New drug shrinks tumors in Hard-to-Treat bladder cancer

Disease control Completed

This study tested enfortumab vedotin, a drug that delivers chemotherapy directly to cancer cells, in 40 Chinese patients with advanced bladder cancer that had worsened after standard treatments. The main goal was to see how many patients' tumors shrank. The trial also looked at h…

Phase 2 • Sponsor: Astellas Pharma China, Inc. • Aim: Disease control

Last updated Jun 27, 2026 07:54 UTC

Astellas Pharma China, Inc.

New drug shrinks tumors in Hard-to-Treat bladder cancer